Prestige Consumer Healthcare's Tax Rate Hits 46.7% As Acquisition Debt Triples Interest Costs

A valuation allowance and $2.1 billion of debt cut reported earnings to $0.53 a share, while the adjusted figure rose to $1.13.

Share
Prestige Consumer Healthcare's Tax Rate Hits 46.7% As Acquisition Debt Triples Interest Costs

Prestige Consumer Healthcare, which sells brands such as Clear Eyes and Breathe Right, saw its effective tax rate reach 46.7% in the September quarter, up from 38.9% a year earlier, after it set up a valuation allowance against deferred tax assets, its 10-Q filed Thursday shows. Quarterly interest expense meanwhile reached $30.0 million, three times the year-earlier level, as borrowing for acquisitions swelled the debt load.

Tax rate and interest squeeze profit

A valuation allowance is an accounting reserve against tax assets the company may not be able to use. The 10-Q says it was the main reason the rate rose, both for the quarter and for the six months, when the rate was 36.7% versus 31.5%. The prior quarter's 10-Q had put the rate at 24.3% and cited other drivers.

Pretax income fell to $47.5 million from $69.1 million. Net income was $25.3 million, or $0.53 a share, against $42.2 million, or $0.86, a year earlier.

Interest expense was $30.0 million versus $10.0 million. Average debt reached $2.1 billion from $1.0 billion, and the average borrowing cost rose to 5.6% from 4.5%. The company also booked a $1.4 million loss on retiring its 2019 notes, replaced by $400.0 million of 6.250% notes due 2034.

Adjusted EPS tells a different story

The company's earnings release put adjusted diluted EPS at $1.13, versus $1.07 a year ago. That adjusted figure adds back a $10.6 million normalized tax adjustment tied to the allowance, worth $0.22 a share, along with acquisition and Pillar5 facility costs.

Revenue rose 22.7% to $336.3 million. Excluding currency and a $65.1 million contribution from the Breathe Right and LaCorium acquisitions, it fell 1.6%, which the company tied to order timing and a decline in Clear Eyes. The 10-Q says shortages, especially of sterile eye care products, have hurt results.

Debt-funded buying spree

Prestige, which sells branded over-the-counter health products through retailers and e-commerce, has grown largely by acquisition. It bought Pillar5, a sterile eye-drop maker, in December 2025 for $109.9 million. It bought Breathe Right and other brands on June 12 for $1,044.9 million in cash, funded with a term loan. It bought Australia's LaCorium Health on July 1 for $152.1 million, borrowing another $95.0 million.

Total debt stood at $2.1 billion at September 30, and cash was $46.5 million. The company cut its fiscal 2027 outlook to $1,280 million to $1,290 million in revenue and $4.48 to $4.55 in adjusted EPS, citing variable Clear Eyes production at Pillar5.

Net receivables grew to $244.1 million from $191.9 million, while the credit-loss allowance against them increased to $24.1 million from $18.2 million.

Sources

More on Prestige Consumer Healthcare

All Prestige Consumer Healthcare (PBH) coverage →